Exagen Registers $150M Shelf With $50M TD Cowen ATM, ~34% Dilution at $5.81
XGN has more than doubled off its 52-week low of $2.59 on light trading volume (0.3× avg).
Summary
Exagen registered a $150 million shelf, including a $50 million at-the-market stock program with TD Cowen that would add 8,605,852 shares — about a third more than the 25,420,340 outstanding — if fully sold at $5.81. No shares have been sold under the program yet.
Key Events · Financing and Capital Events · XGN
-
$50M ATM Registered With TD Cowen
A November 9, 2026 sales agreement lets Exagen sell up to $50.0 million of common stock from time to time through TD Cowen; no sales have been made under the agreement yet.
-
Roughly a Third More Shares at $5.81
At the $5.81 last reported sale price, full use of the ATM means 8,605,852 new shares against 25,420,340 outstanding at September 30, 2026 — about 33.9% dilution, or $3.98 per share immediate dilution to new buyers.
-
Agent Fees and Offering Costs
TD Cowen earns 3.0% of gross proceeds, Exagen reimburses up to $75,000 of the agent's legal expenses, and total offering expenses are estimated at about $125,000 excluding commissions.
-
Perceptive Tranche B Cut and Drawn
Amendments on October 19 and November 9, 2026 reduced Tranche B from $10.0 million to $5.0 million and extended availability to November 15, 2026; Exagen drew the $5.0 million on November 9, 2026.
Analysis · XGN · Industrial Applications And Services
Exagen is putting real numbers on the capital raise it flagged in this morning's 10-Q. The $50.0 million at-the-market program through TD Cowen is now fully registered and can be sold into the market at any time; at the $5.81 last reported sale price, full use would mean 8,605,852 new shares — roughly a third more stock than the 25,420,340 shares outstanding at September 30, 2026. That is meaningful dilution for a company that ended the quarter with $28.1 million in cash and a $6.3 million quarterly net loss, but it also gives management a live funding tap without another negotiated deal. The filing also confirms the Perceptive credit amendments: Tranche B was cut from $10.0 million to $5.0 million and extended to November 15, 2026, and the company drew the $5.0 million on November 9, 2026, which vested 75,000 warrant shares while 450,000 remain subject to future vesting. Nothing has been sold under the ATM yet — this is capacity, not proceeds.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XGN was trading at $5.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $139.5M. The 52-week trading range was $2.59 to $10.27. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.